Journal of Cancer Research and Therapeutics

ORIGINAL ARTICLE
Year
: 2021  |  Volume : 17  |  Issue : 1  |  Page : 88--93

“Christie Regimen” palliative radiotherapy in advanced head-and-neck cancer: A single-center experience


Anurita Srivastava, Narayan Adhikari, Deepak Raj Sonkar, Kishore Singh, Arun Kumar Rathi 
 Department of Radiation Oncology, Lok Nayak Hospital and Associated Maulana Azad Medical College, New Delhi, India

Correspondence Address:
Anurita Srivastava
Room No. 116, Department of Radiation Oncology, Lok Nayak Hospital and Associated Maulana Azad Medical College, New Delhi - 110 002
India

Background: Relevance of aggressive treatment in advanced head neck squamous cell cancers(HNSCC) is debatable in view of expected poor outcome. Long treatment duration only adds up to the cost of treatment without any improvements in outcomes. Aims and Objectives: To assess the outcomes of hypofractionated “Christie” palliative radiotherapy regimen in advanced HNSCC Materials and Methods: Patients of advanced HNSCC registered from June 2015 to June 2019 were treated by parallel pair field technique on Cobalt60 machine (Theatron 780E) to total dose of 50 Gray/16 fractions over 3.2 weeks. Toxicity was scored using Radiation Therapy Oncology Group (RTOG) criteria and response was evaluated as per WHO criteria. Results: Records of 110 patients of HNSCC with mean age of 56.19 years were analysed. Evaluation at 4-8 weeks after radiotherapy resulted in a complete response (CR) in 19.1%, partial response (PR) in 32.7%, stable disease (SD) in 29.1% and progressive disease (PD) in 3.6%, while 15.5% patients did not report for post treatment evaluation. Median progression free survival was 9.52 months (95% CI 5.9 – 13.1 months). The median overall survival was 12.7 ± 2.2 months (95% CI 8.2 – 17.2). Median time to progression after completion of radiotherapy was 84 days. Grade IV dermatitis and mucositis was encountered in 2.7% and 1.8% cases respectively, requiring hospitalization. Conclusion: Christie regimen for advanced HNSCC is a clinically viable option with acceptable outcomes in a resource constrained setting.


How to cite this article:
Srivastava A, Adhikari N, Sonkar DR, Singh K, Rathi AK. “Christie Regimen” palliative radiotherapy in advanced head-and-neck cancer: A single-center experience.J Can Res Ther 2021;17:88-93


How to cite this URL:
Srivastava A, Adhikari N, Sonkar DR, Singh K, Rathi AK. “Christie Regimen” palliative radiotherapy in advanced head-and-neck cancer: A single-center experience. J Can Res Ther [serial online] 2021 [cited 2021 May 9 ];17:88-93
Available from: https://www.cancerjournal.net/article.asp?issn=0973-1482;year=2021;volume=17;issue=1;spage=88;epage=93;aulast=Srivastava;type=0